Skip to main content
Article thumbnail
Location of Repository

Structure-based discovery of β2-adrenergic receptor ligands

By Peter Kolb, Daniel M. Rosenbaum, John J. Irwin, Juan José Fung, Brian K. Kobilka and Brian K. Shoichet

Abstract

Aminergic G protein-coupled receptors (GPCRs) have been a major focus of pharmaceutical research for many years. Due partly to the lack of reliable receptor structures, drug discovery efforts have been largely ligand-based. The recently determined X-ray structure of the β2-adrenergic receptor offers an opportunity to investigate the advantages and limitations inherent in a structure-based approach to ligand discovery against this and related GPCR targets. Approximately 1 million commercially available, “lead-like” molecules were docked against the β2-adrenergic receptor structure. On testing of 25 high-ranking molecules, 6 were active with binding affinities <4 μM, with the best molecule binding with a Ki of 9 nM (95% confidence interval 7–10 nM). Five of these molecules were inverse agonists. The high hit rate, the high affinity of the most potent molecule, the discovery of unprecedented chemotypes among the new inhibitors, and the apparent bias toward inverse agonists among the docking hits, have implications for structure-based approaches against GPCRs that recognize small organic molecules

Topics: Biological Sciences
Publisher: National Academy of Sciences
OAI identifier: oai:pubmedcentral.nih.gov:2672528
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.